Filter by: patients
Home > Community Treatment Reports and Side Effects > Robitussin-DM Treatment Report
What is Robitussin-DM?

Robitussin is a brand of cold and cough medicines produced by Wyeth Consumer Healthcare. Robitussin DM contains the expectorant guaifenesin and the cough suppressant dextromethorphan.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Other 2 1 Efficacy_moderate
Persistent cough 1 1 Efficacy_moderate
thick phlegm 1 1 Efficacy_major
control dyskenisia 1 1 Efficacy_none

See all 2 patients currently taking Robitussin-DM

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 4

Reported Dosages

  9 mL daily 200 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Robitussin-DM (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 2   Course of treatment ended: 67%
Doctor's advice 1   Doctor's advice: 33%

See all 3 patients who’ve stopped taking Robitussin-DM

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Robitussin-DM

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Robitussin-DM

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Robitussin-DM

Always
 1 25%
Usually
 1 25%
Sometimes
 1 25%
Never
 1 25%

Burden

Difficulty being on treatment

Burden of Robitussin-DM

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 4 100%

Cost

Paid out of pocket

Cost of Robitussin-DM

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 2 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 27, 2012.